Jonkoping

• OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting
  2023-507164-39-00 6 2021-12-01 Induction of labour
• Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting
  2022-501874-21-00 6 2020-12-15 Takotsubo syndrome
• The SANT-study - A randomized controlled clinical trial of Streptococcus group A-negative acute tonsillitis in primary health care - a compa … Recruiting
  2023-508542-18-00 6 2019-09-02 Tonsilitis
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 5 2019-01-08 Prostate Cancer
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• EVOLVE-MI Ended recruitment
  2023-509268-26-00 6 2024-01-08 Dyslipidemia
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• Ixekizumab Diabetes Intervention Trial (I-DIT) Ended recruitment
  2023-508588-58-00 4 2022-10-25 Diabetes type 1
• A Randomized Intervention, Multi-Center Study to Determine the Role of Dexamethasone eye drops against proliferative retinopathy of prematur … Ended recruitment
  2023-505318-97-00 5 2022-09-22 Retinopathy of Prematurity
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) Ended recruitment
  2023-504945-30-00 5 2021-03-16 Primary or recurrent non-muscle invasive bladder cancer with intermedi
• A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast … Ended recruitment
  2024-514733-38-00 5 2020-11-03 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early … Ended recruitment
  2022-501102-35-00 5 2019-12-02 Early triple negative breast cancer
• Evaluation of cortisone treatment in children suffering from acute facial nerve paralysis. Ended recruitment
  2024-513430-37-00 6 2019-06-01 Facial Nerve Palsy (Bells Palsy)
• Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction SPIRRIT-HFpEF Ended recruitment
  2024-517448-79-00 5 2017-11-23 Heart failure with preserved ejection fraction
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF) Ended
  2024-511502-24-02 4 2021-08-18 High-risk hyperkalemia
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca

Showing 25–44 of 44 trials